PFIZER INC Derivative, Net Liability Position, Aggregate Fair Value
PFIZER INC (PFE) had Derivative, Net Liability Position, Aggregate Fair Value of $880.00 million as of 2026-06-28, per its 10-Q filed 2026-08-04.
Financial Statements › Notes › Summary of Derivative Instruments › Derivative, Credit Risk Related Contingent Features
us-gaap:DerivativeNetLiabilityPositionAggregateFairValue · last filed 2026-08-04
- 2026-06-28: Derivative, Net Liability Position, Aggregate Fair Value $880.00M.
- 2026-03-29: Derivative, Net Liability Position, Aggregate Fair Value $1.10B.
- 2025-12-31: Derivative, Net Liability Position, Aggregate Fair Value $938.00M.
- 2025-09-28: Derivative, Net Liability Position, Aggregate Fair Value $1.10B.
| Period end | Derivative, Net Liability Position, Aggregate Fair Value |
|---|---|
| 2026-06-28 | $880.00M 10-Q · filed 2026-08-04 |
| 2026-03-29 | $1.10B 10-Q · filed 2026-05-05 |
| 2025-12-31 | $938.00M 10-K · filed 2026-02-26 |
| 2025-09-28 | $1.10B 10-Q · filed 2025-11-04 |
| 2025-06-29 | $1.10B 10-Q · filed 2025-08-05 |
| 2025-03-30 | $646.00M 10-Q · filed 2025-05-05 |
| 2024-12-31 | $741.00M 10-K · filed 2025-02-27 |
| 2024-09-29 | $910.00M 10-Q · filed 2024-11-04 |
| 2024-06-30 | $775.00M 10-Q · filed 2024-08-05 |
| 2024-03-31 | $770.00M 10-Q · filed 2024-05-08 |
| 2023-12-31 | $768.00M 10-K · filed 2024-02-22 |
| 2023-10-01 | $941.00M 10-Q · filed 2023-11-08 |
| 2023-07-02 | $854.00M 10-Q · filed 2023-08-09 |
| 2023-04-02 | $763.00M 10-Q · filed 2023-05-10 |
| 2022-12-31 | $888.00M 10-K · filed 2023-02-23 |
| 2022-10-02 | $595.00M 10-Q · filed 2022-11-09 |
| 2022-07-03 | $362.00M 10-Q · filed 2022-08-10 |
| 2022-04-03 | $568.00M 10-Q · filed 2022-05-11 |
| 2021-12-31 | $372.00M 10-K · filed 2022-02-24 |
| 2021-10-03 | $357.00M 10-Q · filed 2021-11-12 |
| 2021-07-04 | $618.00M 10-Q · filed 2021-08-12 |
| 2021-04-04 | $613.00M 10-Q · filed 2021-05-13 |
| 2020-12-31 | $946.00M 10-K · filed 2021-02-25 |
| 2020-09-27 | $1.10B 10-Q · filed 2020-11-05 |
| 2020-06-28 | $928.00M 10-Q · filed 2020-08-06 |
| 2020-03-29 | $1.10B 10-Q · filed 2020-05-07 |
| 2019-12-31 | $449.00M 10-K · filed 2020-02-27 |
| 2019-09-29 | -$673.00M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $279.00M 10-Q · filed 2019-08-08 |
| 2019-03-31 | $209.00M 10-Q · filed 2019-05-09 |
| 2018-12-31 | $472.00M 10-K · filed 2019-02-28 |
| 2018-09-30 | $545.00M 10-Q · filed 2018-11-08 |
| 2018-07-01 | $413.00M 10-Q · filed 2018-08-09 |
| 2018-04-01 | $540.00M 10-Q · filed 2018-05-10 |
| 2017-12-31 | $336.00M 10-K · filed 2018-02-22 |
| 2017-10-01 | $491.00M 10-Q · filed 2017-11-09 |
| 2017-07-02 | $409.00M 10-Q · filed 2017-08-10 |
| 2017-04-02 | $837.00M 10-Q · filed 2017-05-11 |
| 2016-12-31 | $936.00M 10-K · filed 2017-02-23 |
| 2016-10-02 | $542.00M 10-Q · filed 2016-11-10 |
| 2016-07-03 | $805.00M 10-Q · filed 2016-08-11 |
| 2016-04-03 | $817.00M 10-Q · filed 2016-05-12 |
| 2015-12-31 | $1.10B 10-K · filed 2016-02-29 |
| 2015-09-27 | $852.00M 10-Q · filed 2015-11-05 |
| 2015-06-28 | $933.00M 10-Q · filed 2015-08-06 |
| 2015-03-29 | $729.00M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $233.00M 10-K · filed 2015-02-27 |
| 2014-09-28 | $116.00M 10-Q · filed 2014-11-06 |
| 2014-06-29 | $76.00M 10-Q · filed 2014-08-07 |
| 2014-03-30 | $192.00M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $128.00M 10-K · filed 2014-02-28 |
| 2011-04-03 | $297.00M 10-Q · filed 2011-05-12 |
| 2010-12-31 | $628.00M 10-K · filed 2011-02-28 |
| 2010-10-03 | $1.20B 10-Q · filed 2010-11-12 |
| 2010-07-04 | $860.00M 10-Q · filed 2010-08-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| ABBOTT LABORATORIES (ABT) | United States | $176.045B | 28.47 |
| VERTEX PHARMACEUTICALS INC / MA (VRTX) | United States | $132.481B | 28.56 |
| BRISTOL MYERS SQUIBB CO (BMY) | United States | $125.637B | 12.67 |
| REGENERON PHARMACEUTICALS, INC. (REGN) | United States | $74.751B | 21.53 |
| ALNYLAM PHARMACEUTICALS, INC. (ALNY) | United States | $33.420B | 54.94 |
| Zoetis Inc. (ZTS) | United States | $29.045B | 11.38 |
| INSMED Inc (INSM) | United States | $26.566B | -26.60 |
| Roivant Sciences Ltd. (ROIV) | $26.105B | -96.08 | |
| Royalty Pharma plc (RPRX) | United States | $22.628B | |
| UNITED THERAPEUTICS Corp (UTHR) | United States | $20.249B | 17.64 |